What question did this study set out to answer?

This review examines the use of PSMA-targeted radioligand therapy across different stages of prostate cancer and its potential benefits.

July 8, 2026CancersOpen Access

PSMA-Targeted Radioligand Therapy Beyond the Post-Taxane Setting: A Review of Evidence Across the Prostate Cancer Spectrum

View Full Paper

Ask AI

Bookmark

Authors

Reviewing evidence for PSMA-targeted therapy's effectiveness across prostate cancer stages, highlighting implications for earlier treatment adoption.

This review examines the use of PSMA-targeted radioligand therapy across different stages of prostate cancer and its potential benefits.
Assessment of clinical trial results including VISION, TheraP, PSMAfore, PSMAddition, UpFrontPSMA, BULLSEYE, and LUNAR.
Discussion on patient selection, treatment sequencing, and cost-effectiveness of PSMA-targeted therapies.
Significant overall survival benefit observed with Lu-PSMA combined with enzalutamide compared to enzalutamide alone.
Improved radiographic progression-free survival reported in mHSPC with Lu-PSMA added to standard ADT and ARPI.
Benefits observed in oligometastatic settings, suggesting potential to defer androgen deprivation therapy.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Reviewing evidence for PSMA-targeted therapy's effectiveness across prostate cancer stages, highlighting implications for earlier treatment adoption.